Literature DB >> 25655873

Qualitative and quantitative analysis of MR imaging findings in patients with middle cerebral artery stroke implanted with mesenchymal stem cells.

C P Wanamaker1, S Fakhran1, L M Alhilali2.   

Abstract

BACKGROUND AND
PURPOSE: Mesenchymal stem cells have potential as a regenerative therapy in ischemic stroke. We sought to determine MR imaging findings after mesenchymal stem cell implantation in chronic middle cerebral artery infarcts and to compare brain volume changes in patients with mesenchymal stem cells with those in age-matched healthy controls and controls with chronic stable MCA infarcts.
MATERIALS AND METHODS: We retrospectively identified 5 patients receiving surgical mesenchymal stem cell implantation to an MCA infarct from January 1, 2005, to July 1, 2013, with MR imaging immediately and 1 year postimplantation. Images at both time points were evaluated for any postimplantation complications. Structural image evaluation using normalization of atrophy software was used to determine volume changes between time points and compare them with those in healthy and age- and sex-matched controls with chronic, stable MCA infarcts by using Kruskal-Wallis and Mann-Whitney U tests.
RESULTS: Susceptibility signal loss and enhancement at the implantation site were seen. No teratoma, tumor, or heterotopia was identified. Volumetric analysis showed a trend toward less overall volume loss after mesenchymal stem cell implantation (0.736; 95% CI, -4.15-5.62) compared with that in age- and sex-matched controls with chronic, stable MCA infarcts (-3.59; 95% CI, -12.3 to -5.21; P = .09), with a significantly greater growth-to-loss ratio in infarcted regions (1.30 and 0.78, respectively, P = .02). A trend toward correlation of growth-to-loss ratio with improvement in physical examination findings was seen (r = 0.856, P = .06).
CONCLUSIONS: Postoperative changes consistent with stereotactic implantation were seen, but no teratoma, tumor, or heterotopia was identified. Initial findings suggest a trend toward less volume loss after mesenchymal stem cell implantation compared with that in age- and sex-matched controls with chronic, stable MCA infarcts, with a significantly greater growth-to-loss ratio in the infarcted tissue.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2015        PMID: 25655873      PMCID: PMC8013029          DOI: 10.3174/ajnr.A4232

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  35 in total

1.  Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke.

Authors:  Osamu Honmou; Kiyohiro Houkin; Takuya Matsunaga; Yoshiro Niitsu; Sumio Ishiai; Rie Onodera; Stephen G Waxman; Jeffery D Kocsis
Journal:  Brain       Date:  2011-04-14       Impact factor: 13.501

Review 2.  Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views.

Authors:  Donald G Phinney; Darwin J Prockop
Journal:  Stem Cells       Date:  2007-09-27       Impact factor: 6.277

3.  Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling.

Authors:  S Claiborne Johnston; Shanthi Mendis; Colin D Mathers
Journal:  Lancet Neurol       Date:  2009-02-21       Impact factor: 44.182

4.  Infarct volume is a pivotal biomarker after intra-arterial stroke therapy.

Authors:  Albert J Yoo; Zeshan A Chaudhry; Raul G Nogueira; Michael H Lev; Pamela W Schaefer; Lee H Schwamm; Joshua A Hirsch; R Gilberto González
Journal:  Stroke       Date:  2012-03-15       Impact factor: 7.914

5.  Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.

Authors:  F Durand-Dubief; B Belaroussi; J P Armspach; M Dufour; S Roggerone; S Vukusic; S Hannoun; D Sappey-Marinier; C Confavreux; F Cotton
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

Review 6.  Stem cells and stroke: opportunities, challenges and strategies.

Authors:  Terry C Burns; Gary K Steinberg
Journal:  Expert Opin Biol Ther       Date:  2011-02-16       Impact factor: 4.388

7.  Teratoma formation in immunocompetent mice after syngeneic and allogeneic implantation of germline capable mouse embryonic stem cells.

Authors:  Abdullah Aldahmash; Muhammad Atteya; Mona Elsafadi; May Al-Nbaheen; Husain Adel Al-Mubarak; Radhakrishnan Vishnubalaji; Ali Al-Roalle; Suzan Al-Harbi; Muthurangan Manikandan; Klaus Ingo Matthaei; Amer Mahmood
Journal:  Asian Pac J Cancer Prev       Date:  2013

8.  Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties.

Authors:  Moïra François; Raphaëlle Romieu-Mourez; Sophie Stock-Martineau; Marie-Noëlle Boivin; Jonathan L Bramson; Jacques Galipeau
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

Review 9.  Stem cell-based therapies for ischemic stroke.

Authors:  Lei Hao; Zhongmin Zou; Hong Tian; Yubo Zhang; Huchuan Zhou; Lei Liu
Journal:  Biomed Res Int       Date:  2014-02-26       Impact factor: 3.411

10.  External validation of the MRI-DRAGON score: early prediction of stroke outcome after intravenous thrombolysis.

Authors:  Guillaume Turc; Pierre Aguettaz; Nelly Ponchelle-Dequatre; Hilde Hénon; Olivier Naggara; Xavier Leclerc; Charlotte Cordonnier; Didier Leys; Jean-Louis Mas; Catherine Oppenheim
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

View more
  2 in total

1.  Stem cell transplantation for ischemic stroke.

Authors:  Giorgio Battista Boncoraglio; Michela Ranieri; Anna Bersano; Eugenio A Parati; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2019-05-05

2.  Mesenchymal stem cells protect neurons against hypoxic-ischemic injury via inhibiting parthanatos, necroptosis, and apoptosis, but not autophagy.

Authors:  Deyan Kong; Juehua Zhu; Qian Liu; Yongjun Jiang; Lily Xu; Ning Luo; Zhenqiang Zhao; Qijin Zhai; Hao Zhang; Mingyue Zhu; Xinfeng Liu
Journal:  Cell Mol Neurobiol       Date:  2016-04-04       Impact factor: 5.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.